Matching Pairs Diabetes Oral MedsOnline version NUr115 Oral Diabetic Agents by Concetta Fiorentino 1 Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels. 2 Possible side-effect of impaired platelet function. 3 Enhances glucose-dependent insulin secretion. 4 Usually given once a day. 5 Do not increased insulin secretion. 6 Sensitize body tissue to insulin: stimulates insulin receptor sites. 7 Stimulate pancreas to secrete insulin. 8 Prevents kidneys from reabsorbing glucose. 9 Drug to drug interaction with NSAIDS. 10 Inhibit production of glucose by the liver. 11 Stimulate beta cells of the pancreas. Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity) Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset) Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix) Januvia glipizide Avandia Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl) Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance) Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia) Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus)